newsfilter
← Latest News
Business Wire·

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Data establish maximum tolerated dose, supporting progression of lead neuroplastogen compound EB-003 toward IND-enabling studies and First-in-Human clinical trials Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or